Magnetic resonance imaging following CT or US detection of indeterminate pelvic mass helps women avoid unnecessary surgeries.
Magnetic resonance imaging after diagnosis of an indeterminate pelvic mass reduces the number of unnecessary surgeries or long-term follow up, according to a study published in the American Journal of Roentgenology.
Researchers from Yale University in New Haven, CT undertook a study to assess the clinical impact of pelvic MRI performed following the diagnosis of an indeterminate pelvic mass on ultrasound or CT.
Researchers reviewed radiologic records of 214 females (median age 45.5, ranging from 7 to 84) who underwent pelvic MRI for evaluation of a gynecologic mass detected on a preceding ultrasound or CT examination; 76% had undergone an initial evaluation with ultrasound and 24% with CT. Eighty percent of the women underwent only ultrasound (83%), CT (16%) or PET/CT (1%). Nineteen percent of the 214 subjects underwent imaging on two modalities before MRI. Of those, the second examination was ultrasound (75%) or CT (25%). The time from the first (or second) radiologic examination to MRI was between zero to 98 days, median 27 days.
The results showed that MRI findings altered clinical management of patients in 77% of cases. Surgery was avoided in 36%, and surgery was changed to a more appropriate method (laparoscopy versus laparotomy, involvement or not of a gynecologic oncologist) in an additional 17% of cases.
The researchers concluded that had the subjects not undergone MRI following initial imaging, many would have had unnecessary or inappropriate surgery for their condition.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.